1. Laurus Labs:
Motilal Oswal maintains its ‘Buy’ call on this pharmaceutical company with a target price of Rs 1,110, an upside of 15.7%. Laurus Labs' Q2FY26 revenue surged 36.8%, and net profit soared 9.8x YoY. Strong growth in core businesses, notably higher sales in finished dosage forms and anti-retroviral (ARV) segments, fueled this revenue jump.
Analysts Tushar Manudhane and Aashita Jain expect continued top-line growth, driven by improvements in the ARV and generics segments, plus faster progress in contract development and manufacturing (CDMO) projects. Laurus Labs is also venturing into new areas, investing Rs 500 crore to build an animal health segment, projected to scale up by FY27.
The company plans to invest $600 million (around Rs 5,000 crore) in a new site in Vizag. This facility will expand pharmaceutical manufacturing and R&D, aiming for greater scale and advanced technology.
Manudhane and Jain highlight that better operational efficiency and an improved product mix will boost profits. They believe strong demand in high-margin CDMO and a stable base business will maintain this growth. They project Laurus Labs will achieve a 17% revenue CAGR and a 43.6% net profit CAGR from FY26-28.
2. Polycab India:
Anand Rathi reiterates its ‘Buy’ rating on this cables & wires manufacturer with a target price of Rs 8,868, an upside of 18.1%. Polycab delivered strong Q2FY26 results: net profit surged 55.9% and revenue grew 17% YoY. Analysts Manish Valecha and Surbhi Lodha noted balanced growth across segments, with core wires and cables up 21% and fast-moving electrical goods (FMEG) rising 12%.
Management expects the core wires and cables business to continue its strong performance in H2FY26. It benefits from government infrastructure spending, a rebound in private investment, and ongoing activity in housing and industry. The FMEG segment also anticipates growth, driven by increased fan and switch production, a strategic shift towards higher-margin products, and investments in premium offerings and brand-building.
Valecha and Lodha project higher margins for Polycab, fueled by its shift to premium products and better operating efficiency. The company’s strong brand recognition and distribution network offer a clear competitive edge, driving sustained growth. Given this positive outlook, analysts forecast Polycab India will achieve revenue and net profit CAGRs of 18.9% and 21.9%, respectively, from FY26-FY28.
3. UltraTech Cement:
Deven Choksey reiterates its ‘Buy’ rating on this cement manufacturer with a target price of Rs 14,406, an upside of 20.7%. UltraTech’s Q2FY26 revenue surged 20.3% YoY to Rs 19,606.9 crore, driven by increased cement volumes and improved pricing. Net profit skyrocketed 75.2% to Rs 1,231.6 crore, thanks to cost efficiencies in power and logistics.
Management projects the cement industry will sustain 7-8% growth through FY30, fueled by housing, infrastructure, and a rural recovery. UltraTech plans to strengthen its southern market position, aggressively gain share in the North and West, and expand its premium product range. The company aims for a 240–245 million tonnes per annum capacity by FY29, with an annual capital expenditure of Rs 10,000 crore. A new cables venture, launching in Q3FY26, also signals strategic diversification.
Analyst Yogesh Tiwari observes robust demand across the North, East, and West, driven by strong housing and commercial projects. UltraTech also boosted its retail presence, increasing UltraTech Building Solutions outlets by 38% to 5,084. These outlets now contribute 21% of total sales. Analysts expect revenue to grow at a 19.1% CAGR and net profit at 41.7% from FY26-FY27.
4. Acutaas Chemicals:
IDBI Capital rates Acutaas Chemicals, a speciality chemicals firm, a ‘Buy’ with a target price of Rs 2,141 per share, a 24.9% upside. The company posted strong Q2FY26 results: revenue grew 23.9%, and net profit surged 93.5% YoY. Analysts Jason Soans and Khubaib Abdullah noted that growth in advanced pharmaceutical intermediates drove revenue, while a richer product mix boosted net profit.
Management projects 25% revenue growth for FY26, citing strong demand for key molecules and expanding its contract development and manufacturing (CDMO) business via the Ankleshwar unit. Acutaas expects to finalise three new CDMO contracts soon, each worth Rs 50-100 crore.
Looking ahead, Soans and Abdullah highlight Acutaas’ ambitious goal: achieving Rs 1,000 crore in CDMO revenue by FY28. A Rs 2,500 crore capital expenditure for FY26 will fuel this expansion, targeting high-growth areas like electrolyte additives to maintain momentum. Analysts project Acutaas will deliver a 26.8% revenue CAGR and a 48.6% net profit CAGR from FY26-27.
5. Can Fin Homes:
Axis Direct maintains its ‘Buy’ rating on this housing finance company, with a target price of Rs 985, an upside of 13.9%. The company reported strong Q2FY26 results, surpassing estimates across key metrics. Net interest income (NII) surged 19% YoY, thanks to wider margins. Asset quality also improved, with gross non-performing loans tightening QoQ to a mere 0.9%.
Analysts Dnyanada Vaidya and Abhishek Pandya foresee clearer growth as key markets like Karnataka and Telangana rebound. Can Fin Homes aims for Karnataka loan disbursements to hit Rs 300 crore per month by Q4FY26, aided by simpler property documentation. It also anticipates a gradual recovery in Telangana as loan defaults decrease.
Vaidya and Pandya emphasise the company’s swift expansion into northern and western India, where loan growth exceeds 25-30%. Can Fin Homes targets these non-southern markets to contribute 40% of its business by FY28. Margins should remain healthy, around 3.8%, benefiting from lower funding costs and increased lending to self-employed customers. Analysts project robust annual asset under management and NII growth of 15% and 13% respectively, through FY28.
Note: These recommendations are from various analysts and are not recommendations by Trendlyne.
(You can find all analyst picks here)
